Search results
Results from the WOW.Com Content Network
iNCOVACC (codenamed BBV154) [1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [2] [3] American company Precision Virologics [4] [5] and the Washington University School of Medicine in St Louis, Missouri, United States.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
In results presented in July 2010 to an international conference on Alzheimer's disease held in Hawaii, the company showed that for 34 out of the 35 hospice patients who had been scanned, the initial scan results were confirmed when pathologists counted plaque under a microscope and when a computerized scan of the plaque was performed on ...
Dosing of the 10 patients with Rett syndrome in Part A, the dose escalation portion of the REVEAL Phase 1/2 adolescent/adult trial and the REVEAL Phase 1/2 pediatric trial, has been completed. The dataset includes six patients in cohort two (high dose, 1x10 15 total vector genomes (vg)) and four patients in cohort one (low dose, 5.7x10 14 total ...
The firm, in collaboration with the Government of Odisha, is establishing another facility at Odisha Biotech Park in Bhubaneswar to commence Covaxin production by June 2022. [ 14 ] [ 15 ] In December 2020, Ocugen entered into a partnership with Bharat Biotech to co-develop and exclusively commercialise Covaxin in the US market; [ 16 ] [ 17 ] in ...
We will also continue to enroll patients in the Phase 3 TEBE-AM trial for advanced cutaneous melanoma, with data expected in 2026, and the Phase 3 ATOM trial for adjuvant uveal melanoma.“ Full Year and Fourth Quarter 2024 Highlights (including post-period) Financial Results
In 2012 ivacaftor was designated as an orphan drug, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States.On 31 January 2012, Vertex gained FDA approval [22] of the first drug, Kalydeco, [23] to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation.
A patient's genome may include an inherited or random mutation which affects the probability of developing a disease in the future. [27] For example, Lynch syndrome is a genetic disease that predisposes patients to colorectal and other cancers; early detection can lead to close monitoring that improves the patient's chances of a good outcome. [39]